Skip to main content
. Author manuscript; available in PMC: 2018 Nov 1.
Published in final edited form as: J Thorac Oncol. 2017 Aug 14;12(11):1611–1625. doi: 10.1016/j.jtho.2017.08.002

Figure 1.

Figure 1

Timeline of key advances in targeting ROS1 in lung cancer. Abbreviations: NSCLC, non-small cell lung cancer; ALK, anaplastic lymphoma kinase; FDA, Food and Drug Administration.